Literature DB >> 8550841

Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats.

J L Wautier1, C Zoukourian, O Chappey, M P Wautier, P J Guillausseau, R Cao, O Hori, D Stern, A M Schmidt.   

Abstract

Dysfunctional endothelium is associated with and, likely, predates clinical complications of diabetes mellitus, by promoting increased vascular permeability and thrombogenicity. Irreversible advanced glycation end products (AGEs), resulting from nonenzymatic glycation and oxidation of proteins or lipids, are found in plasma, vessel wall, and tissues and have been linked to the development of diabetic complications. The principal means through which AGEs exert their cellular effects is via specific cellular receptors, one of which, receptor for AGE (RAGE), is expressed by endothelium. We report that blockade of RAGE inhibits AGE-induced impairment of endothelial barrier function, and reverse, in large part, the early vascular hyperpermeability observed in diabetic rats. Inhibition of AGE- and diabetes-mediated hyperpermeability by antioxidants, both in vitro and in vivo, suggested the central role of AGE-RAGE-induced oxidant stress in the development of hyperpermeability. Taken together, these data support the concept that ligation of AGEs by endothelial RAGE induces cellular dysfunction, at least in part by an oxidant-sensitive mechanism, contributing to vascular hyperpermeability in diabetes, and that RAGE is central to this pathologic process.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8550841      PMCID: PMC507085          DOI: 10.1172/JCI118397

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  Protein iodination with solid state lactoperoxidase.

Authors:  G S David; R A Reisfeld
Journal:  Biochemistry       Date:  1974-02-26       Impact factor: 3.162

Review 2.  Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions.

Authors:  A M Schmidt; O Hori; J Brett; S D Yan; J L Wautier; D Stern
Journal:  Arterioscler Thromb       Date:  1994-10

Review 3.  Hemodynamic factors in the genesis of diabetic microangiopathy.

Authors:  H H Parving; G C Viberti; H Keen; J S Christiansen; N A Lassen
Journal:  Metabolism       Date:  1983-09       Impact factor: 8.694

4.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

5.  Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.

Authors:  R Zatz; B R Dunn; T W Meyer; S Anderson; H G Rennke; B M Brenner
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

6.  Increased adhesion of erythrocytes to endothelial cells in diabetes mellitus and its relation to vascular complications.

Authors:  J L Wautier; R C Paton; M P Wautier; D Pintigny; E Abadie; P Passa; J P Caen
Journal:  N Engl J Med       Date:  1981-07-30       Impact factor: 91.245

7.  Increased capillary permeability in diabetes mellitus and its relationship to microvascular angiopathy.

Authors:  G C Viberti
Journal:  Am J Med       Date:  1983-11-30       Impact factor: 4.965

8.  Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications.

Authors:  J L Wautier; M P Wautier; A M Schmidt; G M Anderson; O Hori; C Zoukourian; L Capron; O Chappey; S D Yan; J Brett
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

9.  Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface.

Authors:  A M Schmidt; M Vianna; M Gerlach; J Brett; J Ryan; J Kao; C Esposito; H Hegarty; W Hurley; M Clauss
Journal:  J Biol Chem       Date:  1992-07-25       Impact factor: 5.157

10.  Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease.

Authors:  U Ritthaler; Y Deng; Y Zhang; J Greten; M Abel; B Sido; J Allenberg; G Otto; H Roth; A Bierhaus
Journal:  Am J Pathol       Date:  1995-03       Impact factor: 4.307

View more
  110 in total

Review 1.  [Non-enzymatic glycation and oxidative stress in chronic illnesses and diabetes mellitus].

Authors:  P P Nawroth; A Bierhaus; G E Vogel; M A Hofmann; M Zumbach; P Wahl; R Ziegler
Journal:  Med Klin (Munich)       Date:  1999-01-15

Review 2.  The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses.

Authors:  A M Schmidt; S D Yan; S F Yan; D M Stern
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

3.  The expression of LDL receptor in vessels with blood-brain barrier impairment in a stroke-prone hypertensive model.

Authors:  Masaki Ueno; Bin Wu; Toshitaka Nakagawa; Yukiko Nagai; Masayuki Onodera; Cheng-Long Huang; Takashi Kusaka; Kenji Kanenishi; Haruhiko Sakamoto
Journal:  Histochem Cell Biol       Date:  2010-05-11       Impact factor: 4.304

4.  Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury.

Authors:  Hideto Yonekura; Yasuhiko Yamamoto; Shigeru Sakurai; Ralica G Petrova; Md Joynal Abedin; Hui Li; Kiyoshi Yasui; Masayoshi Takeuchi; Zenji Makita; Shin Takasawa; Hiroshi Okamoto; Takuo Watanabe; Hiroshi Yamamoto
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

5.  Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response.

Authors:  Birgit Liliensiek; Markus A Weigand; Angelika Bierhaus; Werner Nicklas; Michael Kasper; Stefan Hofer; Jens Plachky; Herman-Josef Gröne; Florian C Kurschus; Ann Marie Schmidt; Shi Du Yan; Eike Martin; Erwin Schleicher; David M Stern; G ünterJ Hämmerling G; Peter P Nawroth; Bernd Arnold
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

Review 6.  Uremic Toxicity of Advanced Glycation End Products in CKD.

Authors:  Andréa E M Stinghen; Ziad A Massy; Helen Vlassara; Gary E Striker; Agnès Boullier
Journal:  J Am Soc Nephrol       Date:  2015-08-26       Impact factor: 10.121

Review 7.  Oxidative stress and diabetic complications.

Authors:  Ferdinando Giacco; Michael Brownlee
Journal:  Circ Res       Date:  2010-10-29       Impact factor: 17.367

Review 8.  Smooth muscle cell phenotypic switching in stroke.

Authors:  Marine Poittevin; Pierre Lozeron; Rose Hilal; Bernard I Levy; Tatiana Merkulova-Rainon; Nathalie Kubis
Journal:  Transl Stroke Res       Date:  2013-11-22       Impact factor: 6.829

Review 9.  Advanced-glycation end products in insulin-resistant states.

Authors:  Georgia Soldatos; Mark E Cooper; Karin A M Jandeleit-Dahm
Journal:  Curr Hypertens Rep       Date:  2005-04       Impact factor: 5.369

Review 10.  Pathogenesis of malaria and clinically similar conditions.

Authors:  Ian A Clark; Lisa M Alleva; Alison C Mills; William B Cowden
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.